Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

被引：0
|
作者：
Tomokazu Kishiki
Hiroaki Ohnishi
Tadahiko Masaki
Kouki Ohtsuka
Yasuo Ohkura
Jyunji Furuse
Takashi Watanabe
Masanori Sugiyama
机构：
[1] Kyorin University School of Medicine,Department of Surgery
[2] Kyorin University School of Medicine,Department of Laboratory Medicine
[3] Kyorin University School of Medicine,Department of Pathology
[4] Kyorin University School of Medicine,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Colorectal cancer; PTEN; MET; Anti-EGFR therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：749 / 757
页数：8
相关论文
共 50 条
  • [31] PanitumumabIn Metastatic Colorectal Cancer with Wild-Type KRAS
    Juliane Weber
    Paul L. McCormack
    BioDrugs, 2008, 22 : 403 - 411
  • [32] Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
    Er, Tze-Kiong
    Chen, Chih-Chieh
    Bujanda, Luis
    Herreros-Villanueva, Marta
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [33] Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
    Weber, Juliane
    McCormack, Paul L.
    BIODRUGS, 2008, 22 (06) : 403 - 411
  • [34] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [35] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
  • [36] Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines
    Kumar, S. Sree
    Price, T.
    Hardingham, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S493 - S493
  • [37] Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond
    Chu, Edward
    ONCOLOGY-NEW YORK, 2014, 28 (02): : 96 - 96
  • [38] Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    De Stefano, Alfonso
    Carlomagno, Chiara
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9732 - 9743
  • [39] Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    Alfonso De Stefano
    Chiara Carlomagno
    World Journal of Gastroenterology, 2014, (29) : 9732 - 9743
  • [40] Overall survival of patients with metastatic KRAS wild type colorectal cancer patients treated with anti-EGFR third line monotherapy
    Debska-Szmich, Sylwia
    Krakowska, Magdalena
    Staniecka, Katarzyna
    Krzeptowska, Paulina
    Debski, Jakub
    Dzierzak, Maria
    Wasik, Magdalena
    Gadzinowska, Joanna
    Habib-Lisik, Maja
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (06): : 402 - 405
12345